Analise de custo por resposta de adalimumabe, etanercepte, guselcumabe, infliximabe, ixequizumabe, secuquinumabe e ustequinumabe para tratamento de psoríase em placas moderada a grave sob a perspectiva do Sistema de Saúde Suplementar brasileiro

Fioratti, Cyntia; Valencia-Mendoza, Atanacio; Rachid, Maria Luiza; Rosim, Ricardo; Junqueira, Marcela.
J. bras. econ. saúde (Impr.) ; 10(3): 226-231, dez. 2018. tab, ilus
Artículo en Portugués | LILACS, ECOS | ID: biblio-988156

Documentos relacionados

  1. Biological Therapy Interruption and Re-Treatment in Chronic Plaque Psoriasis.
  2. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.
  3. Network meta-analyses of systemic treatments for psoriasis: a critical appraisal: Original Articles: Jabbar-Lopez ZK, Yiu ZZN, Ward V et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol 2017; 137:1646-54. Sbidian E, Chaimani A, Garcia-Doval I et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2017; 12:CD011535.
  4. Estimate of the cost per responder for treatment with biological therapies of moderate-to-severe plaque psoriasis in Colombia for first-year and maintenance periods.
  5. Retrospective analysis of patients with psoriasis receiving biological therapy: Real-life data.
  6. Survival of biological therapeutics in psoriasis: retrospective analysis of 3-years data in a Turkish registry, PSORTAKSIS.
  7. Onset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis.
  8. A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study.
  9. Efficacy of biologic therapies in psoriasis vulgaris.
  10. Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis.